Skip to content
OpenCapital
Get started

Bioventus BVS Surgical Solutions — Total Net Sales

Other product segments

Pain Treatments
$63.43M+7.7%
Restorative Therapies
$20.64M+4.6%

Similar metrics at other companies

Medline, Inc. logo
MDLNSurgical Solutions — Net Sales
$1.55B+7.4%
Enovis logo
ENOVSurgical — Net Sales
$317.13M+10.8%
MiMedx Group logo
MDXGSurgical — Net Sales
$36.37M+13.2%
TFX
TFXSurgical — Net revenues
$106.79M+12.4%
CONMED logo
CNMDGeneral Surgery — Net Sales
$169.38M-7.4%
Bausch + Lomb logo
BLCOSurgical — Total revenues
$228M+6.5%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×—
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%—
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's surgical solutions — total net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's surgical solutions — total net sales?
Bioventus (BVS) reported surgical solutions — total net sales of $48.03M in Q1 2026.
How has Bioventus's surgical solutions — total net sales changed year-over-year?
Bioventus's surgical solutions — total net sales increased by 6.2% year-over-year, from $45.23M to $48.03M.
What is the long-term trend for Bioventus's surgical solutions — total net sales?
Over 4 years (2021 to 2025), Bioventus's surgical solutions — total net sales has grown at a 23.4% compound annual growth rate (CAGR), from $87.72M to $203.65M.
What does surgical solutions — total net sales mean?
This metric represents the total revenue generated from the sale of products and services within the surgical solutions business unit. It reflects the company's market performance and commercial success in providing specialized medical technologies for orthopedic and surgical procedures. Growth in this segment indicates successful adoption of the company's surgical portfolio by healthcare providers and surgeons.